Evolution of the Average Target: Afya Limited

Evolution of the Average Target - Afya Limited

Evolution of the Target Price: Afya Limited

Evolution of the Target Price - Afya Limited

Changes in Analyst Recommendations: Afya Limited

270fe08cfa45a8c9.jzm4fnNjxheteyQ_moBCGC4sILfErlcQMyR7bHE4Fa8.3gvbHAEysk3ySFJMy8Y4fHx2c_itnjV3dkUNHTtOdMv_fuw2ITKAdclKYQ~ed04c67e73bbfacc430236cc21480c92
10-07 Afya Shares Rise After JPMorgan Upgrade MT
10-07 JPMorgan Upgrades Afya to Overweight From Neutral, $19 Price Target MT
02-24 BofA Securities Downgrades Afya to Neutral From Buy, Price Target is $17 MT
02-13 Afya Shares Fall After Morgan Stanley Downgrade MT
02-13 Morgan Stanley Downgrades Afya to Underweight From Equalweight, Adjusts Price Target to $16 From $17.50 MT
01-16 UBS Downgrades Afya to Neutral From Buy, Adjusts PT to $16 From $18 MT
01-08 UBS Trims Afya Price Target to $18 From $19, Maintains Buy Rating MT
01-07 JPMorgan Downgrades Afya to Neutral From Overweight, Adjusts Price Target to $22 From $24.50 MT
08/09/25 UBS Upgrades Afya to Buy From Neutral, $19 Price Target MT
08/09/25 JPMorgan Upgrades Afya to Overweight, Price Target is $24.50 MT
06/08/25 Afya Shares Rise After Morgan Stanley Upgrade MT
06/08/25 Morgan Stanley Upgrades Afya to Equalweight From Underweight, Adjusts Price Target to $17.50 From $19 MT
29/07/25 Citigroup Upgrades Afya to Neutral From Sell, Adjusts Price Target to $14 From $16 MT
12/06/25 UBS Hikes Afya Price Target to $19.50 From $17.50, Maintains Neutral Rating MT
11/03/25 Morgan Stanley Downgrades Afya to Underweight From Equal Weight, Cuts Price Target to $17 From $19 MT
05/02/25 Bradesco BBI Downgrades Afya to Underperform From Neutral, Adjusts Price Target to $14 From $17 MT
31/01/25 Citigroup Downgrades Afya to Sell From Neutral, Adjusts Price Target to $15 From $18 MT
17/12/24 UBS Cuts Price Target on Afya to $17.50 From $19.50, Keeps Neutral Rating MT
30/08/24 UBS Initiates Coverage on Afya With Neutral Rating, Sets $19.50 Price Target MT
21/06/24 Morgan Stanley Adjusts Price Target on Afya to $19 From $21, Maintains Equalweight Rating MT
27/11/23 JPMorgan Downgrades Afya to Neutral From Overweight, Adjusts Price Target to $23 From $22 MT
22/11/22 Credit Suisse Adjusts Afya's Price Target to $18 From $19, Keeps Outperform Rating MT
13/10/22 UBS Adjusts Afya Price Target to $18 From $21, Maintains Buy Rating MT
08/04/22 Credit Suisse Upgrades Afya to Outperform from Neutral, Adjusts Price Target to $19 from $18 MT
07/03/22 UBS Adjusts Afya Price Target to $21 From $27, Maintains Buy Rating MT

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
+6.88%
- - -15.36%
+16.81%
+27.09%
+22.34%
+59.41%
+46.48%
+46.35%
Average +26.25%
Weighted average by Cap. +10.49%


Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
8
Last Close Price
70.87BRL
Average target price
88.36BRL
Spread / Average Target
+24.67%
High Price Target
98.79BRL
Spread / Highest target
+39.39%
Low Price Target
76.39BRL
Spread / Lowest Target
+7.78%

Analyst Consensus Detail

Analyst consensus - Afya Limited

Consensus revision (last 18 months)

Consensus revision (last 18 months) - Afya Limited
Trader
Investor
Global
Quality
ESG MSCI
-
Ratings Surperformance© - Afya Limited